Loading clinical trials...

An Integrative Model for Palliative Care in End-Stage Liver Disease | Clinical Trials | Clareo Health

COMPLETED

An Integrative Model for Palliative Care in End-Stage Liver Disease

NCT05238779•Virginia Commonwealth University

Summary

The purpose of this research study is to understand the impact of palliative care in ESLD on quality of life, emergency room or hospital visits, and on care provider burden, and to work to develop the best way to provide palliative care in ESLD.

Detailed Description

Patients with end-stage liver disease (ESLD) have multiple symptoms that impact their quality of life and result in more emergency room and hospital visits. Palliative care is a medical model that can help alleviate pain and suffering and reduce need for urgent medical care and can do so while continuing other appropriate medical care. While palliative care consults are used in those with ESLD, despite the pain and suffering that accompanies ESLD, palliative care is often used too little and too late.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Primary participant:
•admission for decompensated cirrhosis, age ≥ 18
•willingness to sign consent
•able to read and understand English
•presence of decompensated cirrhosis with portal hypertension (jaundice, ascites, HE, hepatohydrothorax, AKI, HRS and/or variceal bleeding) or HCC
•Caregiver:
•identified as the primary caregiver of the participant
•age ≥ 18
•willingness to sign consent
•able to read and understand English

Exclusion Criteria

•Primary participant:
•prior liver transplant
•lack of capacity to provide informed consent (in the judgement of the investigator)
•already in receipt of palliative or hospice care
•those who are likely to receive a LT during the index admission
•Caregiver:
•none

Locations (1)

Virginia Commonwealth University

Richmond, Virginia, United States

Key Dates

Start Date

January 6, 2022

Primary Completion Date

December 12, 2022

Completion Date

December 12, 2022

Last Updated

July 7, 2023

Enrollment

ACTUAL participants

Conditions

End Stage Liver DIsease

Interventions

Standard of care including palliative care

OTHER

Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease

NCT06136221

Cirrhosis, LiverEnd Stage Liver DIsease+3 more

View study

COMPLETEDPHASE2/PHASE3

Growth Hormone in Decompensated Liver Cirrhosis

NCT05253287

Liver CirrhosisFibrosis+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 7, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

An Integrative Model for Palliative Care in End-Stage Liver Disease

Inclusion Criteria

Exclusion Criteria

Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease

Growth Hormone in Decompensated Liver Cirrhosis

Longitudinal Study of Mitochondrial Hepatopathies

Evaluation of Frailty and Functional Capacity in End-Stage Liver Disease

Normothermic Liver Preservation Trial

Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation